Paloma Fernández

Paloma Fernández

Auto-generated profile, based on publicly available information

Paloma Fernández

Nemesio Díez Institute of Applied Molecular Medicine. Universidad San Pablo-CEU, Madrid, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in Allergy
Verified
Journal Article
Open access
NCNuria Contreras
Nuria Contreras
AEAndrea Escolar‐Peña
Andrea Escolar‐Peña
MDMaría Isabel Delgado Dolset
María Isabel Delgado Dolset
PFPaloma Fernández
Paloma Fernández
DODavid Obeso
David Obeso
Escribese M. M.Escribese M. M.
Escribese M. M.
Rationale: Biologics are becoming increasingly important in the management of severe asthma. However, little is known about the systemic immunometabolic consequences of Th2 response blockage. Objectives: To provide a better immunometabolic understanding of the effects of mepolizumab and omalizumab treatments by identifying potential biomarkers for monitoring. Methods: In this exploratory longitudinal study severe asthmatic patients were followed for 18 months after initiating mepolizumab ( n = 36) or Omalizumab ( n = 20) treatment. Serum samples were collected before, 6, and 18 months after treatment. Targeted omic approaches were performed to analyze inflammatory metabolites ( n = 35) and proteins ( n = 45). Multiomic integration was performed individually for each treatment applying supervised analysis Data Integration Analysis for Biomarker discovery using Latent cOmponents (DIABLO) framework. Then, potential biomarkers were confirmed using multivariate ROC analyses and correlated with clinical variables along treatment. Measurements and Main Results: Mepolizumab and omalizumab were both effective (improved clinical variables) and showed different and specific metabolic and protein profiles in severe asthmatic patients during treatment. Multiomic integration and multivariate ROC analyses identified specific biomarkers, such as arachidonic acid, palmitoleic acid, oleic acid, propionylcarnitine, bilirubin, CCL11, and TNFSF10, which can explain the differences observed with Mepolizumab treatment over 18 months and significantly correlate with clinical improvement. However, no significant biomolecules and no discriminative multivariate ROC curves were found for Omalizumab treatment. Conclusions: Our results provide a comprehensive insight into the differential effects of mepolizumab and omalizumab on the immunometabolic kinetics of the inflammatory response in severe asthma. We identified a set of biomolecules with potential for monitoring mepolizumab treatment which could be useful for personalized medicine.

27 May 2020
Verified
Book Chapter
Closed access
FRFrancisco Reina
Francisco Reina
MRMiguel A. Reina
Miguel A. Reina
PFPaloma Fernández
Paloma Fernández
XSXavier Sala-Blanch
Xavier Sala-Blanch
ABAndré P. Boezaart
André P. Boezaart
ACAnna Carrera
Anna Carrera

4 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RJRocío Jarcovsky
Rocío Jarcovsky
STSara Temprano-Carazo
Sara Temprano-Carazo
ABAna Bravo
Ana Bravo
SGSantiago Garcés-Fernández
Santiago Garcés-Fernández
BGBlanca Gómez-Barahona
Blanca Gómez-Barahona
Ester Martin-VillarEster Martin-Villar
Ester Martin-Villar
Skin development and adaptation to inflammatory stress require keratinocytes to coordinate changes in cell behaviour with tissue organisation. Cell adhesion and the cortical cytoskeleton support the structural plasticity underlying these responses. Here, using complementary mouse models of global podoplanin deletion and conditional deletion in basal keratinocytes driven by keratin 5-Cre (K5Cre), we identify a role for the small transmembrane glycoprotein podoplanin in maintaining basal layer organisation and coordinating differentiation with barrier acquisition during development, as well as in inflammatory skin remodelling. Podoplanin expression was dynamically regulated during epidermal morphogenesis, becoming enriched in basal epithelial compartments before declining postnatally in the interfollicular epidermis. Both deletion models exhibited basal layer disorganisation, altered division orientation and increased epidermal thickness. Premature or expanded expression of differentiation markers was accompanied by delayed barrier acquisition, indicating that podoplanin loss uncouples differentiation marker expression from functional maturation. Barrier function subsequently recovered despite persistent histological abnormalities. In primary keratinocytes, podoplanin deficiency disrupted junctional actin organisation, reduced ERM phosphorylation and impaired junctional enrichment of pERM and doubly phosphorylated myosin light chain 2 (ppMLC2), despite largely preserved recruitment of adhesion proteins. In adult skin, K5Cre-mediated deletion altered differentiation marker dynamics following topical application of the proinflammatory agent 12-O-tetradecanoylphorbol-13-acetate (TPA), while the epidermal thickening response remained largely comparable to controls. These epidermal changes were accompanied by altered dermal thickness dynamics and an absence of TPA-induced podoplanin expression in dermal fibroblasts. Furthermore, TPA reduced the number of BrdU-retaining cells in the interfollicular epidermis of controls but not K5Cre-mediated conditional podoplanin knockout mice. This difference is consistent with impaired activation or mobilisation of slow-cycling cells, suggesting altered responsiveness within the epidermal stem and progenitor compartment. Together, these findings establish keratinocyte-expressed podoplanin as a regulator of epidermal organisation and functional maturation, with effects extending beyond the epithelium to shape the dermal response to inflammatory challenge.